Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Set On Competing With Merck And Roche, Dr Reddy's Labs Pins Hopes On CETP Drug

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Despite the odds against developing a robust pipeline of innovative drugs, Kallam Anji Reddy, founder and chairman of the $1.36 billion Dr. Reddy's Labs, refuses to give up the chase to discover new drugs
Advertisement

Related Content

INTERVIEW: Dr. Reddy’s CEO On Move From Curing Diseases To Managing Health (Part 2 of 2)
American Heart Association Scientific Sessions, In Brief
American Heart Association Scientific Sessions, In Brief
Dr. Reddy's To Close Atlanta Facility In Reorganization; Focus On Key Markets To Drive Revenues To $3 Billion By 2013
Advertisement
UsernamePublicRestriction

Register

SC070660

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel